259 related articles for article (PubMed ID: 32807949)
1. Epigenomic analysis of Parkinson's disease neurons identifies Tet2 loss as neuroprotective.
Marshall LL; Killinger BA; Ensink E; Li P; Li KX; Cui W; Lubben N; Weiland M; Wang X; Gordevicius J; Coetzee GA; Ma J; Jovinge S; Labrie V
Nat Neurosci; 2020 Oct; 23(10):1203-1214. PubMed ID: 32807949
[TBL] [Abstract][Full Text] [Related]
2. TET2-mediated Cdkn2A DNA hydroxymethylation in midbrain dopaminergic neuron injury of Parkinson's disease.
Wu TT; Liu T; Li X; Chen YJ; Chen TJ; Zhu XY; Chen JL; Li Q; Liu Y; Feng Y; Wu YC
Hum Mol Genet; 2020 May; 29(8):1239-1252. PubMed ID: 32037456
[TBL] [Abstract][Full Text] [Related]
3. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
5. Hemispheric asymmetry in the human brain and in Parkinson's disease is linked to divergent epigenetic patterns in neurons.
Li P; Ensink E; Lang S; Marshall L; Schilthuis M; Lamp J; Vega I; Labrie V
Genome Biol; 2020 Mar; 21(1):61. PubMed ID: 32151270
[TBL] [Abstract][Full Text] [Related]
6. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
7. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
Wang X; Feng Z; Li Q; Yi B; Xu Q
Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
[TBL] [Abstract][Full Text] [Related]
8. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.
Deplus R; Delatte B; Schwinn MK; Defrance M; Méndez J; Murphy N; Dawson MA; Volkmar M; Putmans P; Calonne E; Shih AH; Levine RL; Bernard O; Mercher T; Solary E; Urh M; Daniels DL; Fuks F
EMBO J; 2013 Mar; 32(5):645-55. PubMed ID: 23353889
[TBL] [Abstract][Full Text] [Related]
9. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity.
Liu R; Jin Y; Tang WH; Qin L; Zhang X; Tellides G; Hwa J; Yu J; Martin KA
Circulation; 2013 Oct; 128(18):2047-57. PubMed ID: 24077167
[TBL] [Abstract][Full Text] [Related]
10. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract][Full Text] [Related]
11. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
Rasmussen KD; Berest I; Keβler S; Nishimura K; Simón-Carrasco L; Vassiliou GS; Pedersen MT; Christensen J; Zaugg JB; Helin K
Genome Res; 2019 Apr; 29(4):564-575. PubMed ID: 30796038
[TBL] [Abstract][Full Text] [Related]
12. An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling.
Lee M; Zhou Y; Huang Y
J Vis Exp; 2017 Dec; (130):. PubMed ID: 29286410
[TBL] [Abstract][Full Text] [Related]
13. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein overexpression induces epigenomic dysregulation of glutamate signaling and locomotor pathways.
Schaffner SL; Wassouf Z; Lazaro DF; Xylaki M; Gladish N; Lin DTS; MacIsaac J; Ramadori K; Hentrich T; Schulze-Hentrich JM; Outeiro TF; Kobor MS
Hum Mol Genet; 2022 Oct; 31(21):3694-3714. PubMed ID: 35567546
[TBL] [Abstract][Full Text] [Related]
15. TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.
Liu Y; Peng W; Qu K; Lin X; Zeng Z; Chen J; Wei D; Wang Z
DNA Cell Biol; 2018 Jun; 37(6):517-523. PubMed ID: 29653065
[TBL] [Abstract][Full Text] [Related]
16. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation.
Hon GC; Song CX; Du T; Jin F; Selvaraj S; Lee AY; Yen CA; Ye Z; Mao SQ; Wang BA; Kuan S; Edsall LE; Zhao BS; Xu GL; He C; Ren B
Mol Cell; 2014 Oct; 56(2):286-297. PubMed ID: 25263596
[TBL] [Abstract][Full Text] [Related]
17. Novel Mutations and Decreased Expression of the Epigenetic Regulator
Potus F; Pauciulo MW; Cook EK; Zhu N; Hsieh A; Welch CL; Shen Y; Tian L; Lima P; Mewburn J; D'Arsigny CL; Lutz KA; Coleman AW; Damico R; Snetsinger B; Martin AY; Hassoun PM; Nichols WC; Chung WK; Rauh MJ; Archer SL
Circulation; 2020 Jun; 141(24):1986-2000. PubMed ID: 32192357
[TBL] [Abstract][Full Text] [Related]
18. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
19. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
20. Association of high 5-hydroxymethylcytosine levels with Ten Eleven Translocation 2 overexpression and inflammation in Sjögren's syndrome patients.
Lagos C; Carvajal P; Castro I; Jara D; González S; Aguilera S; Barrera MJ; Quest AFG; Bahamondes V; Molina C; Urzúa U; Hermoso MA; Leyton C; González MJ
Clin Immunol; 2018 Nov; 196():85-96. PubMed ID: 29894742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
